Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

NCT01449058 is registered in ClinicalTrials.gov with Array BioPharma as lead sponsor.

NCT NCT01449058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01449058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Lead sponsor
Array BioPharma
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2012
Completion date
August 15, 2017
Enrollment
139 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

advanced and selected solid tumors, aml, high risk and very high risk mds